Dr.
Details for the 2024 AACR abstracts are as follows:
JAB-26766: a small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity
Poster Presentation:
Session: PO.ET09.01 - DNA Reactive Agents
JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2. JAB-26766 as a single agent shows potent in vivo anti-tumor activities, which can be further enhanced through combination with
JAB-30355: A highly potent, orally bioavailable p53 Y220C reactivator
Poster Presentation:
Session: PO.ET09.09 - Novel Antitumor Agents 4
JAB-30355 is a potent and selective p53 Y220C reactivator. JAB-30355 exhibited dose-dependent anti-tumor activity, inducing tumor stasis or regression in multiple CDX and PDX models of ovarian cancer, pancreatic cancer, gastric cancer, and small cell lung cancer, with overall good tolerability. A phase I/IIa clinical trial to evaluate the safety and efficacy of JAB-30355 in patients with advanced solid tumor is ongoing in
The 2024 AACR Annual Meeting will be held in
About Jacobio
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in